Asia Pacific Contraceptive Drugs and Devices Market Outlook 2031
The Asia Pacific contraceptive drugs and devices market size was USD 7.27 Billion in 2022 and is anticipated to reach USD 17.42 Billion by 2031 register a considerable CAGR 10.2% during the forecast period, 2023–2031. The growth of the market is attributed to the growing focus toward the requirement of family planning and avoiding unplanned pregnancy.
Contraceptives are the name set to medicines and other devices that are utilized to prevent unwanted pregnancy. Contraception is characterized as the intentional avoidance of conception using different devices, sexual practices, synthetic compounds, drugs, or surgical methods. Hence, any device or act whose object is to keep a lady from becoming pregnant can be considered as a contraceptive.
In any friendly setting viable contraception permits a couple to partake in an actual relationship unafraid of an undesirable pregnancy and guarantees sufficient opportunity to have kids when wanted. Some boundary strategies, similar to male and female condoms, additionally provide twin benefit of assurance from sexually transmitted diseases.
The outbreak of COVID19 pandemic has impacted the contraceptives drugs and devices market. The demand of drugs and devices is declined by around 50% to 60% in 2020. The disruption in supply chain, economic impact, consumer confidence, and other factors have negatively influenced the market growth.
Asia Pacific Contraceptive Drugs and Devices Market Trends, Drivers, Restraints, and Opportunities
- The requirement to avoid unwanted pregnancies, especially in teenage women, is expected to drive the market growth.
- The increase in use of contraception in young women along with rise in higher educational attainment is anticipated to spur the growth of market.
- Increase in awareness of modern contraception, and rise in use of oral pills are expected to boost the market in the coming years.
- Health risks associated with the use of contraceptives and availability of alternate contraceptive methods can hamper the growth of the market.
- Lack of social acceptance can create challenges for the market growth.
- Increasing incidence of STDs and the rapid increase in population is one of the major drivers of the market.
Scope of The Asia Pacific Contraceptive Drugs and Devices Market Report
The Asia Pacific contraceptive drugs and devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Contraceptive Drugs and Devices Market - Asia Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Devices [Diaphragms, Sponges, IUD, Condoms, Cervical Caps, Vaginal Rings, and Others], Drugs [Oral Contraceptives, Topical Contraceptives, and Contraceptive Injectable]), and Gender (Male and Female)
|
|
Geographical Scope
|
India, Japan, China, South Korea, and Rest of Asia Pacific
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Pfizer Inc.; CooperSurgical, Inc.; Bayer AG; Merck & Co., Inc.; and Allergan PLC
|
Asia Pacific Contraceptive Drugs and Devices Market Segment Insights
Oral contraceptive segment to hold a major market share
In terms of products, the market is bifurcated into devices and drugs. The devices segment is further classified as diaphragms, sponges, IUD, condoms, cervical caps, vaginal rings, and others. The drugs segment is categorized as oral contraceptives, topical contraceptives, and contraceptive injectable. The oral contraceptives segment is projected to expand at a considerable CAGR during the forecast period as oral contraceptives pills is seen as easy method of contraception in the industry.
They act by disallowing implantation inside the uterus whenever taken during 2-3 days of sexual contact. The effortlessness of their use makes them an optimal preventative on the lookout. These are effectively marketed across the locale by organizations, and in this manner, effortlessly consumed by a huge part of the population.
Female segment is anticipated to constitute a key market share
On the basis of gender, the market is segregated into male and female. The female segment is expected to constitute a key share of the market during the projected period, as it regulates menstrual cycle and makes periods less painful. It can be helpful for females in many ways such as banish hormonal acne, reduces risk of uterine cancer, and declines risk of ovarian cysts.
The market in India is estimated to expand at a robust pace
Based on geography, the market can be classified as India, Japan, China, South Korea, and Rest of Asia Pacific. The market in India is anticipated to grow at a rapid pace during the forecast period due to increasing awareness regarding family planning from government state bodies.
Segments
The Asia Pacific contraceptive drugs and devices market is segmented on the basis of:
Products
- Devices
- Diaphragms
- Sponges
- IUD
- Condoms
- Cervical Caps
- Vaginal Rings
- Others
- Drugs
- Oral Contraceptives
- Topical Contraceptives
- Contraceptive Injectable
Gender
Geography
- India
- Japan
- China
- South Korea
- Rest of Asia Pacific
Key Players
Competitive Landscape
The key players competing in the Asia Pacific contraceptive drugs and devices market are Pfizer Inc.; CooperSurgical, Inc.; Bayer AG; Merck & Co., Inc.; and Allergan PLC.
Request For Customization
Enquiry Before Buying
Speak With Analyst
